A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to recent findings by rare cancer researcher Dr. Taran Gujral, head of Fred Hutch's ...

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

The Risk Estimation of Tumor REcurrence After Transplant score accurately predicted hepatocellular carcinoma recurrence after liver transplantation.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

HCC occurred in 1.27% of patients with PBC, which is lower than the recommended threshold for cost-effective surveillance.

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

koya979 – stock.adobe.com “Two competitors. Two samples. One microscopic finish line,” declared Sperm Racing boss Eric Zhu in his race “manifesto.” The teen tech entrepreneur ...

1 Department of Medicine, Division of Endocrinology; 2 Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California Microscopic appearance of the fine ...